(Alliance News) - Scancell Holdings PLC on Monday reported positive data from an ongoing trial on patients receiving a treatment combination for advanced melanoma, a skin cancer.

Nivolumab-based treatment (N+AVD) improves progression-free survival in advanced-stage Hodgkin’s lymphoma patients compared ...

Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

Arbutus Biopharma (ABUS) and Barinthus Biotherapeutics (BRNS) announced new preliminary data from the Phase 2a IM-PROVE II clinical trial of ...

Functional cure is defined by AASLD as sustained HBsAg loss and hepatitis B virus DNA <LLOQ for 6 months off-treatment. Data cut off was September 30, 2024, for lab data and October 8, 2024, for ...

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously ...

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024New CM24 biomarkers data presented during the third quarter of ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

After five years, combination treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) and chemotherapy continues to ...